Accelrys Acquires Qumas - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Accelrys Acquires Qumas

Accelrys, a provider of scientific lifecycle management solutions, has acquired Ireland-based Qumas, a global provider of cloud-based and on-premises enterprise compliance software supporting regulatory and quality operations in life sciences, for $50 million.The Qumas acquisition further extends Accelrys’ informatics portfolio with the addition of mission-critical, end-to-end document, and process management compliance solutions. Qumas’s quality management solutions supported by content and business process management capabilities will assist users to manage the scientific lifecycle by reducing regulatory risks, lowering quality costs, improving compliance effectiveness, and increasing operational efficiency in bringing new products to market. Research, laboratory, and manufacturing informatics applications such as the Accelrys ELN (Electronic Lab Notebook), Accelrys LIMS (Laboratory Information Management System), Accelrys LES ( Lab Execution System) and Accelrys Discoverant for Operational Intelligence will function as data sources as well as integration points for the compliance and quality business systems managed by Qumas for CAPA, annual performance reports, and other submissions.

Source: Accelrys


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns

Click here